middle.news
How AdAlta’s $1.3M Rights Issue Fuels Its Immunotherapy Ambitions
9:30am on Friday 13th of June, 2025 AEST
•
Healthcare
Read Story
How AdAlta’s $1.3M Rights Issue Fuels Its Immunotherapy Ambitions
9:30am on Friday 13th of June, 2025 AEST
Key Points
Final $0.2 million shortfall placed with a single sophisticated investor
Total funds raised under the rights issue reach approximately $1.3 million
Proceeds to support CAR-T licensing, business development of AD-214 and WD-34, and working capital
Administrative error led to director overallocation, breaching ASX Listing Rule 10.11
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Adalta (ASX:1AD)
OPEN ARTICLE